Ahmed M Bayoumi1, Gregory S Zaric. 1. The Centre for Research on Inner City Health, The Keenan Research Centre in the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ont. ahmed.bayoumi@utoronto.ca
Abstract
BACKGROUND: The cost-effectiveness of Canada's only supervised injection facility has not been rigorously evaluated. We estimated the impact of the facility on survival, rates of HIV and hepatitis C virus infection, referral to methadone maintenance treatment and associated costs. METHODS: We simulated the population of Vancouver, British Columbia, including injection drug users and persons infected with HIV and hepatitis C virus. The model used a time horizon of 10 years and the perspective of the health care system. We compared the situation of the supervised injection facility with one that had no facility but that had other interventions, such as needle-exchange programs. The effects considered were decreased needle sharing, increased use of safe injection practices and increased referral to methadone maintenance treatment. Outcomes included life-years gained, costs, and incremental cost-effectiveness ratios discounted at 5% per year. RESULTS: Focusing on the base assumption of decreased needle sharing as the only effect of the supervised injection facility, we found that the facility was associated with an incremental net savings of almost $14 million and 920 life-years gained over 10 years. When we also considered the health effect of increased use of safe injection practices, the incremental net savings increased to more than $20 million and the number of life-years gained to 1070. Further increases were estimated when we considered all 3 health benefits: the incremental net savings was more than $18 million and the number of life-years gained 1175. Results were sensitive to assumptions related to injection frequency, the risk of HIV transmission through needle sharing, the frequency of safe injection practices among users of the facility, the costs of HIV-related care and of operating the facility, and the proportion of users who inject in the facility. INTERPRETATION: Vancouver's supervised injection site is associated with improved health and cost savings, even with conservative estimates of efficacy.
BACKGROUND: The cost-effectiveness of Canada's only supervised injection facility has not been rigorously evaluated. We estimated the impact of the facility on survival, rates of HIV and hepatitis C virus infection, referral to methadone maintenance treatment and associated costs. METHODS: We simulated the population of Vancouver, British Columbia, including injection drug users and persons infected with HIV and hepatitis C virus. The model used a time horizon of 10 years and the perspective of the health care system. We compared the situation of the supervised injection facility with one that had no facility but that had other interventions, such as needle-exchange programs. The effects considered were decreased needle sharing, increased use of safe injection practices and increased referral to methadone maintenance treatment. Outcomes included life-years gained, costs, and incremental cost-effectiveness ratios discounted at 5% per year. RESULTS: Focusing on the base assumption of decreased needle sharing as the only effect of the supervised injection facility, we found that the facility was associated with an incremental net savings of almost $14 million and 920 life-years gained over 10 years. When we also considered the health effect of increased use of safe injection practices, the incremental net savings increased to more than $20 million and the number of life-years gained to 1070. Further increases were estimated when we considered all 3 health benefits: the incremental net savings was more than $18 million and the number of life-years gained 1175. Results were sensitive to assumptions related to injection frequency, the risk of HIV transmission through needle sharing, the frequency of safe injection practices among users of the facility, the costs of HIV-related care and of operating the facility, and the proportion of users who inject in the facility. INTERPRETATION: Vancouver's supervised injection site is associated with improved health and cost savings, even with conservative estimates of efficacy.
Authors: Jo-Anne Stoltz; Evan Wood; Will Small; Kathy Li; Mark Tyndall; Julio Montaner; Thomas Kerr Journal: J Public Health (Oxf) Date: 2007-01-17 Impact factor: 2.341
Authors: F Kapadia; M H Latka; S M Hudson; E T Golub; J V Campbell; S Bailey; V Frye; R S Garfein Journal: Drug Alcohol Depend Date: 2007-02-27 Impact factor: 4.492
Authors: Adrian R Levy; Douglas James; Karissa M Johnston; Robert S Hogg; P Richard Harrigan; Brian P Harrigan; Boris Sobolev; Julio S Montaner Journal: Lancet Infect Dis Date: 2006-03 Impact factor: 25.071
Authors: David Goodman-Meza; Maria Elena Medina-Mora; Carlos Magis-Rodríguez; Raphael J Landovitz; Steve Shoptaw; Dan Werb Journal: Am J Public Health Date: 2018-11-29 Impact factor: 9.308
Authors: Don C Des Jarlais; Kamyar Arasteh; Courtney McKnight; Holly Hagan; David C Perlman; Salaam Semaan Journal: Am J Public Health Date: 2011-05-12 Impact factor: 9.308
Authors: Ava John-Baptiste; Man Wah Yeung; Victoria Leung; Gabrielle van der Velde; Murray Krahn Journal: Pharmacoeconomics Date: 2012-11-01 Impact factor: 4.981
Authors: Michelle Olding; Andrew Ivsins; Samara Mayer; Alex Betsos; Jade Boyd; Christy Sutherland; Coco Culbertson; Thomas Kerr; Ryan McNeil Journal: Am J Public Health Date: 2020-04-16 Impact factor: 9.308